The availability of high-throughput genotyping and large collaborative clinical networks creating well-characterized patient populations with DNA repositories has facilitated genome-wide scans and candidate gene studies to identify susceptibility alleles for the development of interstitial lung disease. The association of pulmonary fibrosis with rare inherited disorders, and the variable susceptibility of inbred mouse strains to this disease indicate that pulmonary fibrosis is determined by genetic factors. Sarcoidosis represents a complex disease with racial and ethnic differences in disease prevalence, and evidence of familial clustering. Familial aggregation of sarcoidosis from ‘A Case-Control Etiologic Study of Sarcoidosis’ (ACCESS) reveals a familial odds ratio (OR) of sarcoidosis of 5.8 (95% CI 2.1–15.9) for sibs and 3.8 (95% CI 1.2–11.3) for parents. Several HLA class II alleles have been associated with either increased or decreased risk of sarcoidosis, and results vary depending on study populations of different ethnicity. Genome-wide screening has conclusively identified linkage to chromosome 5q11and the development of sarcoidosis, and HLA genes and BTNL2 are susceptibility genes located in this region. Familial aggregation of idiopathic interstitial pneumonia (IIP) has been established by several groups, and a large US-based study suggests autosomal dominant inheritance with reduced penetrance; furthermore, cigarette smoking was associated with affection status among siblings (OR = 3.6, 95% CI 1.3–9.8, p = 0.01). Families demonstrate more than one type of IIP, suggesting various subtypes of IIP may share a common pathogenesis. Genome-wide linkage scans in familial interstitial pneumonia demonstrate linkage to chromosomes 4, 5 and 11. Candidate gene studies indicate that surfactant protein C and telomerase are susceptibility genes for the development of pulmonary fibrosis. Future challenges include determining how multiple susceptibility alleles interact with each other and environmental factors resulting in disease risk and multiple phenotypes, and determining the mechanism of action and cellular pathways involving susceptibility alleles. Further insight into these areas may lead to new therapeutic interventions.

Keywords:
Sarcoidosis, Candidate gene studies, Linkage analysis, Interstitial pneumonia, familial, Interstitial pneumonia, idiopathic
1.
Javaheri S, et al: Idiopathic pulmonary fibrosis in monozygotic twins: the importance of genetic predisposition. Chest 1980;78:591–594.
2.
Solliday NH, et al: Familial chronic interstitial pneumonia. Am Rev Respir Dis 1973;108:193–204.
3.
Bonanni PP, Frymoyer JW, Jacox RF: A family study of idiopathic pulmonary fibrosis: a possible dysproteinemic and genetically determined disease. Am J Med 1965;39:411–421.
4.
Hughes EW: Familial interstitial pulmonary fibrosis. Thorax 1964;19:515–525.
5.
Swaye P, et al: Familial Hamman-Rich syndrome. Chest 1969;55:7–12.
6.
Bitterman PB, et al: Familial idiopathic pulmonary fibrosis: evidence of lung inflammation in unaffected members. N Engl J Med 1986;314:1343–1347.
7.
Lee HL, et al: Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest 2005;127:2034–2041.
8.
Hodgson U, Laitinen T, Tukiainen P: Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002;57:338–342.
9.
Depinho RA, Kaplan KL: The Hermansky-Pudlak syndrome: report of three cases and review of pathophysiology and management considerations. Medicine 1985;64:192–202.
10.
Riccardi V: Von Recklinghausen neurofibromatosis. N Engl J Med 1981;305:1617–1627.
11.
Harris J, Waltuck B, Swenson E: The pathophysiology of the lungs in tuberous sclerosis: a case report and literature review. Am Rev Respir Dis 1969;100:379–387.
12.
Makle SK, Pardee N, Martin CJ: Involvement of the lung in tuberous sclerosis. Chest 1970;58:538–540.
13.
Terry R, Sperry W, Brodoff B: Adult lipoidosis resembling Neimann-Pick disease. Am J Pathol 1954;30:263–286.
14.
Schneider E, et al: Severe pulmonary involvement in adult Gaucher’s disease: report of three cases and review of the literature. Am J Med 1977;63:475–480.
15.
Auwerx J, et al: Defective host defence mechanisms in a family with hypocalciuric hypercalcaemia and coexisting interstitial lung disease. Clin Exp Immunol 1985;62:57–64.
16.
Thomas AQ, et al: Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002;165:1322–1328.
17.
Polakoff PL, Horn BR, Scherer OR: Prevalence of radiographic abnormalities among Northern California shipyard workers. Ann NY Acad Sci 1979;33:333–339.
18.
Selikoff IJ, Lilis R, Nicholson WJ: Asbestos disease in United States shipyards. Ann NY Acad Sci 1979;330:293–311.
19.
Ortiz LA, et al: Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 1998;24:721–743.
20.
Rossi G, et al: Susceptibility to experimental interstitial lung disease is modified by immune- and non-immune related genes. Am Rev Respir Dis 1987;135:448–455.
21.
Corsini E, et al: A protective role for T lymphocytes in asbestos-induced pulmonary inflammation and collagen deposition. Am J Respir Cell Mol Biol 1994;11:531–539.
22.
Warshamana GS, et al: Susceptibility to asbestos-induced and transforming growth factor-β1-induced fibroproliferative lung disease in two strains of mice. Am J Respir Cell Mol Biol 2002;27:705–713.
23.
Franko AJ, et al: Evidence for two patterns of inheritance of sensitivity to induction of lung fibrosis in mice by radiation, one of which involves two genes. Radiat Res 1996;146:68–74.
24.
Haston CK, Travis EL: Murine susceptibility to radiation-induced pulmonary fibrosis is influenced by a genetic factor implicated in susceptibility to bleomycin-induced pulmonary fibrosis. Cancer Res 1997;57:5286–5291.
25.
Sharplin J, Franko A: Quantitative histological study of strain-dependent differences in the effects of irradiation on mouse lung during the early phase. Radiat Res 1989;119:1–14.
26.
Haston CK, et al: Inheritance of susceptibility to bleomycin-induced pulmonary fibrosis in the mouse. Cancer Res 1996;56:2596–2601.
27.
Haston CK, et al: Murine candidate bleomycin induced pulmonary fibrosis susceptibility genes identified by gene expression and sequence analysis of linkage regions. J Med Genet 2005;42:464–473.
28.
Haston CK, et al: Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Hum Mol Genet 2002;11:1855–1863.
29.
Lemay AM, Haston CK: Bleomycin-induced pulmonary fibrosis susceptibility genes in AcB/BcA recombinant congenic mice. Physiol Genomics 2005;23:54–61.
30.
Katsuma S, et al: Molecular monitoring of bleomycin-induced pulmonary fibrosis by cDNA microarray-based gene expression profiling. Biochem Biophys Res Commun 2001;288:747–751.
31.
Haston CK, et al: Universal and radiation-specific loci influence murine susceptibility to radiation-induced pulmonary fibrosis. Cancer Res 2002;62:3782–3788.
32.
Rybicki BA, et al: Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001;164:2085–2091.
33.
Rybicki BA, et al: Familial risk ratio of sarcoidosis in African-American sibs and parents. Am J Epidemiol 2001;153:188–193.
34.
Buck AA, Mc KV: Epidemiologic investigations of sarcoidosis. III. Serum proteins; syphilis; association with tuberculosis: familial aggregation. Am J Hyg 1961;74:174–188.
35.
Harrington D, et al: Familial analysis of 91 families. Sarcoidosis 1994;11:240–243.
36.
Headings VE, et al: Familial sarcoidosis with multiple occurrences in eleven families: a possible mechanism of inheritance. Ann NY Acad Sci 1976;278:377–385.
37.
Moura M, et al: Sarcoidosis and heredity: 3 familial cases. Rev Pneumol Clin 1990;46:28–30.
38.
Wiman LG: Familial occurrence of sarcoidosis. Scand J Respir Dis 1972;80(suppl):115–119.
39.
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736–755.
40.
Berlin M, et al: HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997;156:1601–1605.
41.
Bogunia-Kubik K, et al: HLA-DRB1*03, DRB1*11 or DRB1*12 and their respective DRB3 specificities in clinical variants of sarcoidosis. Tissue Antigens 2001;57:87–90.
42.
Foley PJ, et al: Human leukocyte antigen-DRB1 position 11 residues are a common protective marker for sarcoidosis. Am J Respir Cell Mol Biol 2001;25:272–277.
43.
Gardner J, et al: HLA associations in sarcoidosis: a study of two ethnic groups. Thorax 1984;39:19–22.
44.
Ina Y, et al: HLA and sarcoidosis in the Japanese. Chest 1989;95:1257–1261.
45.
Ishihara M, et al: Molecular genetic studies of HLA class II alleles in sarcoidosis. Tissue Antigens 1994;43:238–241.
46.
Martinetti M, et al: ‘The sarcoidosis map’: a joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995;152:557–564.
47.
Swider C, et al: TNF-α and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis. Eur Cytokine Netw 1999;10:143–146.
48.
Sato H, et al: HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 2002;27:406–412.
49.
Mrazek F, et al: Association of tumour necrosis factor-α, lymphotoxin-α and HLA-DRB1 gene polymorphisms with Lofgren’s syndrome in Czech patients with sarcoidosis. Tissue Antigens 2005;65:163–171.
50.
Seitzer U, Gerdes J, Muller-Quernheim J: Genotyping in the MHC locus: potential for defining predictive markers in sarcoidosis. Respir Res 2002;3:6.
51.
Grunewald J, Eklund A, Olerup O: Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med 2004;169:696–702.
52.
Rossman MD, et al: HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003;73:720–735.
53.
Maliarik M, et al: Analysis of HLA-DPB1 polymorphisms in African-Americans with sarcoidosis. Am J Respir Crit Care Med 1998;158:111–114.
54.
Maliarik MJ, et al: Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. Am J Respir Crit Care Med 1998;158:1566–1570.
55.
Alia P, et al: Association between ACE gene I/D polymorphism and clinical presentation and prognosis of sarcoidosis. Scand J Clin Lab Invest 2005,65:691–697.
56.
McGrath DS, et al: Ace gene I/D polymorphism and sarcoidosis pulmonary disease severity. Am J Respir Crit Care Med 2001;164:197–201.
57.
Niimi T, et al: Vitamin D receptor gene polymorphism and calcium metabolism in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:266–269.
58.
Niimi T, et al: Lack of association with interleukin 1 receptor antagonist and interleukin-1β gene polymorphisms in sarcoidosis patients. Respir Med 2000;94:1038–1042.
59.
Kruit A, et al: Transforming growth factor-β gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest 2006;129:1584–1591.
60.
Bogunia-Kubik K, et al: HSP70-hom gene single nucleotide (+2763 G/A and +2437 C/T) polymorphisms in sarcoidosis. Int J Immunogenet 2006;33:135–140.
61.
Pabst S, et al: Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis. Clin Exp Immunol 2006;143:420–426.
62.
Kanazawa N, et al: Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-κB activation: common genetic etiology with Blau syndrome. Blood 2005;105:1195–1197.
63.
Martin TM, et al: Uveitis in patients with sarcoidosis is not associated with mutations in NOD2 (CARD15). Am J Ophthalmol 2003;136:933–935.
64.
Sabounchi-Schutt F, et al: Changes in bronchoalveolar lavage fluid proteins in sarcoidosis: a proteomics approach. Eur Respir J 2003;21:414–420.
65.
Spagnolo P, et al: C-C chemokine receptor 5 gene variants in relation to lung disease in sarcoidosis. Am J Respir Crit Care Med 2005;172:721–728.
66.
Zorzetto M, et al: Complement receptor 1 gene polymorphisms in sarcoidosis. Am J Respir Cell Mol Biol 2002;27:17–23.
67.
Takada T, et al: Polymorphism in RANTES chemokine promoter affects extent of sarcoidosis in a Japanese population. Tissue Antigens 2001;58:293–298.
68.
Akahoshi M, et al: Association between IFNA genotype and the risk of sarcoidosis. Hum Genet 2004;114:503–509.
69.
Rybicki BA, et al: The BTNL2 gene and sarcoidosis susceptibility in African Americans and Whites. Am J Hum Genet 2005;77:491–499.
70.
Iannuzzi MC, et al: Genome-wide search for sarcoidosis susceptibility genes in African Americans. Genes Immun 2005;6:509–518.
71.
Schurmann M, et al: Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med 2001;164:840–846.
72.
Valentonyte R, et al: Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005;37:357–364.
73.
Gray-McGuire C, et al: Genetic characterization and fine mapping of susceptibility loci for sarcoidosis in African Americans on chromosome 5. Hum Genet 2006;120:420–430.
74.
Tsukahara M, Kajii T: Interstitial pulmonary fibrosis in two sisters: possible autosomal recessive inheritance. Jinrui Idengaku Zasshi 1983;28:263–267.
75.
Adelman AG, Chertkow G, Hayton RC: Familial fibrocystic pulmonary dysplasia: a detailed family study. Can Med Assoc J 1966;95:603–610.
76.
McKusick VA, Fisher AM: Congenial cystic disease of the lung with progressive pulmonary fibrosis and carcinomatosis. Ann Intern Med 1958;48:774–790.
77.
Musk AW, et al: Genetic studies in familial fibrosing alveolitis. Possible linkage with immunoglobulin allotypes (Gm). Chest 1986;89:206–210.
78.
Marshall R, et al: Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000;55:143–146.
79.
Steele MP, et al: Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005;172:1146–1152.
80.
Yang IV, et al: Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med 2007;175:45–54.
81.
Hodgson U, et al: ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am J Hum Genet 2006;79:149–154.
82.
Tsakiri KD, et al: Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007;104:7552–7557.
83.
Whitsett JA, Weaver TE: Hydrophobic surfactant proteins in lung function and disease. N Engl J Med 2002;347:2141–2148.
84.
Nogee LM, et al: Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am J Respir Crit Care Med 2000;161:973–981.
85.
Nogee LM, et al: A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001;344:573–579.
86.
Chibbar R, et al: Nonspecific interstitial pneumonia and usual interstitial pneumonia with mutation in surfactant protein C in familial pulmonary fibrosis. Mod Pathol 2004;17:973–980.
87.
Lawson WE, et al: Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 2004;59:977–980.
88.
Selman M, et al: Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Genet 2003;113:542–550. Epub 2003.
89.
Armaniaos MY, et al: Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007;356:1317–1326.
90.
Cottin V: Clinical genetics for the pulmonologist: introduction. Respiration 2007;74:3–7.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.